Active clinical trials for "Dengue"

This cluster randomised trial will evaluate the efficacy of Wolbachia-infected Aedes aegytpi mosquitoes in reducing dengue cases in Yogyakarta City, Indonesia

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-752 in healthy subjects

Design and Outcomes This research study is designed as open-label, sequential dose-escalating clinical trial. There will be two phases of enrollment. In the first phase, pediatric dengue patients with body weight greater than 30 kg will be recruited. The first six volunteers will be administered with 400 μg/kg every 24 hours for a total of three times. The last six volunteers will be administered with 600 μg/kg every 24 hours for a total of three times. In the second phase, pediatric dengue patients with body weight between 15 to 30 kg will be recruited. Similar to the first phase, the first six and the last six volunteers will be administered with 400 μg/kg and 600 μg/kg every 24 hours for a total of three times, respectively. A total of 24 volunteers will be recruited from Faculty of Medicine Siriraj hospitals

The purpose of this study was to describe the neutralizing antibody response against each dengue serotype at 1 month post second dose of TDV or placebo in dengue-naive adolescent participants.

This study aims to investigate the effect of metformin as host-directed therapy in obese/overweight patients with dengue Primary Objective To evaluate the safety and tolerability of metformin in obese/overweight young adults and children with dengue Secondary Objectives To assess the effect of metformin therapy in obese/overweight patients with dengue on physiological, clinical and virological parameters To assess the immunomodulation effects of metformin therapy in obese/overweight patients with dengue To assess difference in gene expression between treatment group compared to non-treatment population

Dengue is the most common viral illness spread by mosquitos. It is important to diagnose dengue to prompt adequate therapy and initiate local mosquito control. Easy to use point of care tests are needed to improve dengue diagnosis. Oral fluid collection may be a simple, non-invasive way to diagnose dengue in the community. However, it is currently unknown if oral fluid is an accurate way to diagnose dengue and if the use of a specialized oral fluid collector could help to improve dengue diagnosis. In this study, the investigators will analyze the oral fluid of suspected dengue patients compared to serum samples for dengue diagnosis. From this information the investigators will be able to determine if oral fluid is a convenient way to diagnose dengue and if the oral fluid collector aids in improving diagnosis.

This is an observational study for 5 years, and aims to determine the risk of developing dengue among Philippine children who are eligible to receive the dengue vaccine during the DOH mass dengue vaccination, by dengue serostatus at baseline.

This retrospective observational study aims to determine the probability of the risk of dengue transmission through a model based on epidemiological, entomological, socioeconomic, demographic, and landscape variables in the El Vergel neighborhood in the municipality of Tapachula, Chiapas, Mexico. The main question it aims to answer is: 1. Is it possible to identify the risk determinants of dengue transmission by developing a probabilistic model based on the landscape analysis of epidemiological, entomological, sociodemographic, and landscape variables in an endemic urban area of the municipality of Tapachula, Chiapas, Mexico? Participants will be selected from a registry obtained from the Secretary of Health of cases of dengue fever, which will be contrasted with the entomological, socioeconomic, demographic, and landscape variables in the El Vergel neighborhood in Tapachula, Chiapas, Mexico. They will be not contacted or sampled for biologic testing in any shape or form, only the data already collected from the health services will be used.

The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to PRNT50 at baseline, or anti-non-structural protein 1 [NS1] test Post-dose 3) in the Colombian study sites of CYD15, CYD13, CYD29, CYD64, CYD65 trials in order to allow appropriate access to care until the completion of 10 years after the last CYD Dengue Vaccine received by each participant

The purpose of this study is evaluate the role of anti-d in dengue fever.